Datum Källa Rubrik Typ Alternativ
2023-05-31 OssDsign Årsstämma har hållits i OssDsign AB Pressreleaser Ladda ner | Visa Stäng
2023-05-31 OssDsign Annual General Meeting held in OssDsign AB Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 31 May 2023 | OssDsign

Annual General Meeting held in OssDsign AB

The annual general meeting resolved: 

–    to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2022;

–    that the company’s result shall be carried forward in new account and that no dividend shall be paid; 

–    to grant the board members and the CEO discharge from liability for the financial year 2022; 

–    that the board of directors shall consist of six ordinary members without deputy members, to re-elect Simon Cartmell, Anders Qvarnström, Håkan Engqvist, Newton Aguiar, Viktor Drvota and Jill Shiaparelli as ordinary board members, and to re-elect Simon Cartmell as chairman of the board; 

–    that a registered accounting firm shall be elected as auditor and to re-elect Ernst & Young AB as the company’s auditor;

–    that fees payable to the board members until the end of the next annual general meeting shall amount to a total of SEK 1,250,000 out of which SEK 350,000 shall be paid to the chairman, SEK 250,000 to each of Anders Qvarnström, Newton Aguiar and Jill Schiaparelli, and SEK 150,000 to Håkan Engqvist;

–    that fees payable to the auditor is to be paid in accordance with approved invoices; 

–    on an authorization for the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures through which the company’s share capital may be increased by an amount corresponding to not more than 20 per cent of the share capital after such issue(s); and

–    to change the limits in the articles of association with respect to share capital and number of shares whereby the company’s share capital shall be not less than SEK than SEK 4,375,000 and not more than SEK 17,500,000 and the number of shares in the company shall be no less than 70,000,000 and no more than 280,000,000. 

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Mob: +46 73 382 43 90
morten.henneveld@ossdsign.com
Certified Adviser:
Erik Penser Bank AB is the Company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
The information was submitted for publication, through the agency of the contact persons set out above, on 31 May 2023, 13:30 CET.

About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
 

2023-05-24 Penser Access Penser Access: Exponentiell tillväxt för Catalyst - OssDsign Pressreleaser Visa Stäng
2023-05-24 Redeye Redeye: OssDsign Q1 - Steep acceleration of sales Pressreleaser Ladda ner | Visa Stäng
2023-05-23 OssDsign OssDsign AB (publ) publishes Q1 2023 Interim Report Rapporter Ladda ner | Visa Stäng
2023-05-23 OssDsign OssDsign AB (publ) publicerar delårsrapport för första kvartalet 2023 Rapporter Ladda ner | Visa Stäng
2023-05-09 OssDsign OssDsign AB: 1 000 patienter behandlade med OssDsign® Catalyst i USA Pressreleaser Ladda ner | Visa Stäng
2023-05-09 OssDsign OssDsign AB: 1,000 patients treated with OssDsign® Catalyst in the U.S. Pressreleaser Ladda ner | Visa Stäng
2023-04-27 OssDsign OssDsign AB: OssDsign publishes Annual Report 2022 Pressreleaser Ladda ner | Visa Stäng
2023-04-27 OssDsign OssDsign AB: OssDsign publicerar Årsredovisning 2022 Pressreleaser Ladda ner | Visa Stäng
2023-04-27 OssDsign OssDsign AB: KALLELSE TILL ÅRSSTÄMMA I OSSDSIGN AB Pressreleaser Ladda ner | Visa Stäng
2023-04-27 OssDsign OssDsign AB: NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB Pressreleaser Ladda ner | Visa Stäng
2023-04-27 OssDsign OssDsign AB: OssDsign når kommersiell milstolpe med 750 implantat sålda i Tyskland Pressreleaser Ladda ner | Visa Stäng
2023-04-27 OssDsign OssDsign AB: OssDsign reaches commercial milestone of 750 implants sold in Germany Pressreleaser Ladda ner | Visa Stäng
2023-03-20 OssDsign OssDsign AB: OssDsign increases operational efficiency and reduces Cranial PSI lead time by up to 40 percent Pressreleaser Ladda ner | Visa Stäng
2023-03-20 OssDsign OssDsign AB: OssDsign effektiviserar sin tillverkning och minskar ledtiden för Cranial PSI med upp till 40 procent Pressreleaser Ladda ner | Visa Stäng
2023-03-14 OssDsign OssDsign AB: OssDsign når kommersiell milstolpe - 200 sålda implantat i Frankrike Pressreleaser Ladda ner | Visa Stäng
2023-03-14 OssDsign OssDsign AB: OssDsign reaches commercial milestone of 200 implants in France Pressreleaser Ladda ner | Visa Stäng
2023-02-22 Penser Access Penser Access: Inne i kraftfull tillväxtfas - OssDsign Pressreleaser Visa Stäng
2023-02-22 Redeye Redeye: OssDsign Q4 - Delivering well in tough conditions Pressreleaser Ladda ner | Visa Stäng
2023-02-21 OssDsign OssDsign AB (publ) publishes Year-end Report 2022 Pressreleaser Ladda ner | Visa Stäng
2023-02-21 OssDsign OssDsign AB (publ) publicerar bokslutskommuniké 2022 Pressreleaser Ladda ner | Visa Stäng
2023-01-10 OssDsign OssDsign AB: OssDsign Catalyst 1cc är nu lanserad och fullt tillgänglig på den amerikanska marknaden Pressreleaser Ladda ner | Visa Stäng
2023-01-09 OssDsign OssDsign AB: OssDsign når milstolpe - 500 patienter behandlade med OssDsign® Catalyst i USA Pressreleaser Ladda ner | Visa Stäng
2023-01-04 OssDsign OssDsign AB: Den första patientrapporten med OssDsign Catalyst visar fullständig ryggradsfusion sex månader efter steloperation Pressreleaser Ladda ner | Visa Stäng
2022-12-16 OssDsign OssDsign AB: Långtidsuppföljning fortsätter visa låga komplikationsnivåer vid behandling med OssDsign Cranial PSI Pressreleaser Ladda ner | Visa Stäng
2022-11-29 OssDsign OssDsign AB completes a directed new share issue raising proceeds of approximately SEK 65.6 million Pressreleaser Ladda ner | Visa Stäng
2022-11-29 OssDsign OssDsign AB genomför en riktad nyemission av aktier och tillförs därigenom cirka 65,6 miljoner kronor Pressreleaser Ladda ner | Visa Stäng
2022-11-29 OssDsign OssDsign AB avser att genomföra en riktad nyemission av aktier Pressreleaser Ladda ner | Visa Stäng
2022-11-29 OssDsign OssDsign AB intends to carry out a directed new share issue Pressreleaser Ladda ner | Visa Stäng
2022-11-29 Penser Access Penser Access: Interview with OssDsign - Erik Penser Bank - 28 november 2022 Analyser Visa Stäng
2022-11-23 Penser Access Penser Access: Ytterligare ett försäljningsmässigt starkt kvartal - OssDsign Analyser Visa Stäng
2022-11-23 Redeye Redeye: OssDsign Q3 - Catalyst positively surprises, but still a difficult climate Analyser Ladda ner | Visa Stäng
2022-11-22 OssDsign OssDsign AB (publ) publicerar delårsrapport för tredje kvartalet 2022 Pressreleaser Ladda ner | Visa Stäng
2022-11-22 OssDsign OssDsign AB (publ) publishes Q3 2022 Interim Report Pressreleaser Ladda ner | Visa Stäng
2022-11-17 OssDsign OssDsign AB: De första resultaten från en långtidsuppföljning av OssDsign Catalyst visar noll procent produktrelaterade komplikationer Pressreleaser Ladda ner | Visa Stäng
2022-11-09 OssDsign OssDsign AB: OssDsign når milstolpen 100 patienter i sitt PROPEL-register tidigare än väntat Pressreleaser Ladda ner | Visa Stäng
2022-11-03 OssDsign OssDsign AB: OssDsign utökar Catalyst-portföljen och lanserar en ny produkt anpassad för fler typer av kirurgiska ingrepp Pressreleaser Ladda ner | Visa Stäng
2022-09-29 OssDsign OssDsign AB: BioStock Investor Meeting: Interview with OssDsign Pressreleaser Visa Stäng
2022-09-29 OssDsign OssDsign AB: BioStock Investor Meeting: Intervju med OssDsign Pressreleaser Visa Stäng
2022-09-26 OssDsign OssDsign AB: Ny vetenskaplig publikation av den hittills största fallstudien av OssDsign Cranial PSI i USA visar positiva behandlingsresultat samt total avsaknad av implantatrelaterade komplikationer Pressreleaser Ladda ner | Visa Stäng
2022-09-22 OssDsign OssDsign AB: BioStock Investor Meeting: OssDsign presents Pressreleaser Visa Stäng
2022-09-22 OssDsign OssDsign AB: BioStock Investor Meeting: OssDsign presenterar Pressreleaser Visa Stäng
2022-09-13 Penser Access Penser Access: Interview with OssDsign - Erik Penser Bank - September 12th 2022 Analyser Visa Stäng
2022-08-24 Penser Access Penser Access: USA-marknaden driver kraftig försäljningsökning - OssDsign Analyser Visa Stäng
2022-08-24 Redeye Redeye: OssDsign - A taste of a better market outlook Analyser Ladda ner | Visa Stäng
2022-08-23 OssDsign OssDsign AB (publ) publicerar delårsrapport för andra kvartalet 2022 Pressreleaser Ladda ner | Visa Stäng
2022-08-23 OssDsign OssDsign AB (publ) publishes Q2 2022 Interim Report Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

14 May 2024 | Kvartalsrapport 2024-Q1
21 May 2024 | Årsstämma 2023
22 May 2024 | Årligutdelning
20 Aug 2024 | Kvartalsrapport 2024-Q2
5 Nov 2024 | Kvartalsrapport 2024-Q3